Composition
- Active substance
- repaglinide
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Repaglinide Sun
- Active substance
- repaglinide
- Therapeutic area
- Diabetes Mellitus, Type 2
- Marketing authorisation holder
- Sun Pharmaceutical Industries B.V.
- Status
- Application withdrawn
- EMA product number
- EMEA/H/C/001145
EMA designations
- Orphan medicine
- No
- Conditional approval
- No
- Biosimilar
- No
- Generic
- Yes
- Accelerated assessment
- No
- Additional monitoring
- No
- Patient safety information
- No